These agents are designed to preferentially promote the antiinflammatory functions of GRα, such as the inhibition of NF‐κB, while minimizing the transactivation of genes responsible for metabolic side effects, offering the potential for a more precise and safer treatment for stress‐related cancers [93]. Here, NFKB1 is linked to cancer.